Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [31] The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials
    Rizos, Evangelos C.
    Tagkas, Christos F.
    Asimakopoulos, Alexandros-Georgios I.
    Tsimihodimos, Vasileios
    Anastasiou, Georgia
    Rizzo, Manfredi
    Agouridis, Aris P.
    Ntzani, Evangelia E.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2024, 38 (07)
  • [32] Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
    Hassanabad, Mortaza E.
    Abad, Zahra F. H.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (03) : 1893 - 1896
  • [33] Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
    Dadwani, Rahul S.
    Wan, Wen
    Skandari, M. Reza
    Huang, Elbert S.
    MDM POLICY & PRACTICE, 2023, 8 (02)
  • [34] Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus
    Kim, Chee Hae
    Hwang, In-Chang
    Choi, Hong-Mi
    Ahn, Chang Ho
    Yoon, Yeonyee E.
    Cho, Goo-Yeong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 364 : 104 - 111
  • [35] Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Winiarska, Agata
    Knysak, Monika
    Nabrdalik, Katarzyna
    Gumprecht, Janusz
    Stompor, Tomasz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [36] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [37] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [38] Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
    Muller, Dion R. P.
    Stenvers, Dirk J.
    Malekzadeh, Arjan
    Holleman, Frederik
    Painter, Rebecca C.
    Siegelaar, Sarah E.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [39] Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
    Baviera, Marta
    Foresta, Andreana
    Colacioppo, Pierluca
    Macaluso, Giulia
    Roncaglioni, Maria Carla
    Tettamanti, Mauro
    Fortino, Ida
    Genovese, Stefano
    Caruso, Irene
    Giorgino, Francesco
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [40] GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns
    Dimitriadis, George D.
    Lambadiari, Vaia
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04) : E52 - E53
12345